Ann: Quarterly Shareholder Update - December 2017, page-12

I do hope you are right for the LOXL2 being the catalyst.
I myself have made many predictions previously: Bronchitol, Boehringer milestone payment, Second indication milestone.. however all fall to nothing, and that made me start thinking about their strategy and model if it is in the best interest of shareholders, or the company?
The problem with the sp is: it is not being manipulated down, there is simply no buying interest on the back of repeated story being sold to us.

Phamaxis need to create real potential, at least a indicative takeover deal on the table, to make investors feel that the interests from the "big pharmas" are actually there.